Trillium Asset Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$11.3M Buy
81,412
+2,757
+4% +$386K 0.38% 75
2025
Q4
$10.1M Sell
78,655
-19,940
-20% -$2.42M 0.31% 80
2025
Q3
$10.9M Sell
98,595
-3,921
-4% -$446K 0.29% 85
2025
Q2
$11.4M Sell
102,516
-2,640
-3% -$281K 0.31% 85
2025
Q1
$11.8M Sell
105,156
-40,297
-28% -$4.16M 0.34% 86
2024
Q4
$13.4M Sell
145,453
-10,464
-7% -$942K 0.35% 84
2024
Q3
$13.1M Sell
155,917
-5,311
-3% -$405K 0.32% 86
2024
Q2
$11.1M Sell
161,228
-2,901
-2% -$194K 0.28% 88
2024
Q1
$12M Buy
164,129
+32,792
+25% +$2.52M 0.31% 89
2023
Q4
$10.6M Sell
131,337
-364
-0.3% -$28.3K 0.29% 90
2023
Q3
$9.87M Sell
131,701
-1,435
-1% -$110K 0.3% 88
2023
Q2
$10.3M Buy
133,136
+37,396
+39% +$2.98M 0.29% 95
2023
Q1
$7.87M Buy
95,740
+13
+0% +$1.08K 0.23% 94
2022
Q4
$8.22M Sell
95,727
-4,760
-5% -$377K 0.25% 98
2022
Q3
$6.2M Sell
100,487
-1,359
-1% -$85.7K 0.2% 109
2022
Q2
$6.29M Sell
101,846
-5,017
-5% -$311K 0.19% 108
2022
Q1
$6.35M Sell
106,863
-98,480
-48% -$6.3M 0.17% 115
2021
Q4
$14.9M Buy
205,343
+2,668
+1% +$184K 0.35% 87
2021
Q3
$14.2M Buy
202,675
+6,153
+3% +$432K 0.37% 85
2021
Q2
$13.5M Buy
196,522
+407
+0.2% +$27.2K 0.37% 85
2021
Q1
$12.7M Buy
196,115
+483
+0.2% +$31.1K 0.4% 82
2020
Q4
$11.4M Sell
195,632
-31,327
-14% -$1.89M 0.41% 80
2020
Q3
$14.3M Sell
226,959
-1,755
-0.8% -$122K 0.6% 61
2020
Q2
$17.6M Sell
228,714
-21,064
-8% -$1.61M 0.75% 48
2020
Q1
$18.7M Buy
249,778
+10,444
+4% +$722K 0.98% 31
2019
Q4
$15.6M Sell
239,334
-30,800
-11% -$2.01M 0.69% 48
2019
Q3
$17.1M Buy
270,134
+112,436
+71% +$7.35M 0.8% 38
2019
Q2
$10.7M Sell
157,698
-16,235
-9% -$1.07M 0.51% 71
2019
Q1
$11.3M Buy
173,933
+195
+0.1% +$13K 0.57% 65
2018
Q4
$10.9M Sell
173,738
-1,910
-1% -$134K 0.63% 61
2018
Q3
$13.6M Buy
175,648
+28,213
+19% +$2.13M 0.68% 54
2018
Q2
$10.4M Buy
147,435
+73,759
+100% +$5.21M 0.56% 71
2018
Q1
$5.55M Buy
73,676
+12,708
+21% +$1.01M 0.31% 107
2017
Q4
$4.37M Sell
60,968
-709
-1% -$53.8K 0.24% 117
2017
Q3
$5M Sell
61,677
-1,107
-2% -$84.6K 0.29% 109
2017
Q2
$4.44M Buy
62,784
+13,300
+27% +$885K 0.27% 116
2017
Q1
$3.36M Sell
49,484
-46,499
-48% -$3.27M 0.21% 125
2016
Q4
$6.87M Sell
95,983
-81,663
-46% -$6.07M 0.45% 85
2016
Q3
$14.1M Sell
177,646
-75,142
-30% -$6.1M 0.9% 37
2016
Q2
$21.1M Sell
252,788
-6,207
-2% -$551K 1.39% 8
2016
Q1
$23.8M Buy
258,995
+46,258
+22% +$4.17M 1.58% 5
2015
Q4
$21.5M Sell
212,737
-14,275
-6% -$1.49M 1.45% 12
2015
Q3
$22.3M Buy
227,012
+1,563
+0.7% +$174K 1.56% 10
2015
Q2
$26.4M Buy
225,449
+1,743
+0.8% +$190K 1.69% 7
2015
Q1
$22M Sell
223,706
-59,554
-21% -$6.05M 1.42% 7
2014
Q4
$26.7M Buy
283,260
+22,144
+8% +$2.29M 1.81% 5
2014
Q3
$27.8M Buy
261,116
+17,483
+7% +$1.71M 2.4% 2
2014
Q2
$20.2M Buy
243,633
+17,661
+8% +$1.37M 1.73% 8
2014
Q1
$16M Buy
225,972
+8,122
+4% +$637K 1.51% 13
2013
Q4
$16.4M Buy
217,850
+41,963
+24% +$2.92M 1.61% 6
2013
Q3
$11.1M Buy
+175,887
New +$10.5M 1.23% 23

Other funds holding GILD

Trillium Asset Management's GILD Position: Q1 2026 in Review

Trillium Asset Management increased its Gilead Sciences (GILD) stake by 3.5% in Q1 2026, buying an estimated $386K and bringing the position to 81,412 shares worth $11.3M. The position accounts for 0.38% of the portfolio, ranked #75.

Trillium Asset Management first reported a position in GILD in Q3 2013 and has held it in 51 quarters since. The position peaked at $27.8M in Q3 2014. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Trillium Asset Management held 81,412 shares of Gilead Sciences worth $11.3M as of Q1 2026.
  • Trillium Asset Management bought 2,757 Gilead Sciences shares in Q1 2026, an estimated $386K.
  • Gilead Sciences made up 0.38% of Trillium Asset Management's portfolio in Q1 2026, its #75 holding.
  • Trillium Asset Management first reported a position in Gilead Sciences in Q3 2013 and has held it in 51 quarters since.
  • Trillium Asset Management's Gilead Sciences position peaked at $27.8M in Q3 2014.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Trillium Asset Management's 13F filing for Q1 2026, filed 11 May 2026.